Until 1980, the U.S. was similar to other countries in per capita spending and life expectancy. Princeton University sociology professor Paul Starr, PhD, said high inflation and sluggish economic growth in the late 1970s hurt countries’ abilities to afford healthcare. The difference was “other countries have been able to put limits on healthcare prices and spending” while the U.S. relied on market forces.

CMS has approved an extension of Maryland’s model of offering a fixed payment for most hospital services, allowing physician practices and nursing homes to voluntarily participate in a program that has saved Medicare hundreds of millions of dollars.

Iowa’s “supplemental payment plan” for nursing homes was rejected by CMS over concerns about having county hospitals assume the licenses of for-profit nursing homes.

A data report released by the Kaiser Family Foundation and the Peterson Center on Healthcare showed the U.S. has higher prices for many healthcare services compared to other high-income countries, including on MRIs and joint replacements, and how some prices have risen faster than inflation.

As a candidate, President Donald Trump had criticized pharma companies for “getting away with murder.” In remarks on Friday, May 11, he did bash the industry’s lobbying power while also lumping in insurance companies, distributors and pharmacy benefit managers (PBMs) as part of the “broken system” that has sent drug prices soaring.

Year-over-year price growth was 2.2 percent in April 2018, which Altarum said was fractionally above the March rate, setting a six-year high for price growth in the sector. Hospital price growth fell slightly to 3.7 percent.

Four states held primary elections on May 8, kicking off a busy election season that will see most Tuesdays from now until mid-September having one or more states’ voters casting ballots. Judging by the latest poll from the Kaiser Family Foundation, healthcare will be a major issue for many in the coming months.

President Donald Trump is set to deliver a speech on pharmaceutical prices on May 11—but rather than matching his campaign rhetoric saying drug industry is “getting away with murder,” he’s expected to be cheered by pharma companies for calling for foreign countries to pay more for drugs, rather than bring down prices in the U.S.